C- myc , not HER-2 / neu , can predict recurrence and mortality of patients with node-negative breast cancer

Breast Cancer Research

Table 4 Mortality and overall survival in 181 node-negative breast cancer patients after different adjuvant systemic therapies or no therapy

Subgroup		n	Mortality (n [%])	OS (P)
Chemotherapy (n = 61)
c-myc	Amplified	19	1 (5.3)	0.7442
	Nonamplified	42	3 (7.1)
HER-2/neu	Amplified	26	0 (0.0)	0.1042
	Nonamplified	35	4 (11.4)
Endocrine therapy (n= 99)
c-myc	Amplified	15	1 (6.7)	0.9846
	Nonamplified	84	6 (7.1)
HER-2/neu	Amplified	22	2 (9.1)	0.8307
	Nonamplified	77	5 (6.5)
No therapy (n = 21)
c-myc	Amplified	5	2 (40.0)	0.0098*
	Nonamplified	16	1 (6.3)
HER-2/neu	Amplified	7	1 (14.3)	0.5649
	Nonamplified	14	2 (14.3)

ISSN: 1465-542X